Postintensive care syndrome in COVID-19. Unicentric pilot study. Calm does not come after the storm

Rodrı́guez, E.; Gimeno, Francesc Puchades; Angulo, Aida Ezzeddine; Samper, Juan Asensio; Ruiz, Cristina Saiz; Alarcón, María Dolores López

doi:10.1016/j.medcle.2021.11.013

Cited by 2 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study conducted with 135 COVID-19 patients, sensory impairment was detected in 20 (14.8%) patients, while 29 (25%) patients described numbness, burning, and tingling [38]. In a study conducted with 29 patients that were followed up for an average of 24 days in the intensive care unit for COVID-19 infection, the incidence of neuropathic pain within 4-6 weeks after discharge was reported as 21% [14]. In comparison, in this study, sensory dysfunction was detected in 18 (18.6%) patients, neuropathic pain was detected in 41 (42.2%) patients based on the scores obtained from the DN-4 questionnaire, and 47 (48.5%) patients described numbness, burning, and tingling after the COVID-19 infection.…”

Section: Discussionmentioning

confidence: 98%

“…The prevalence of neuropathic pain in patients with COVID-19 infection reported in the literature varies between 0.4% and 25% [14,29,30,35,36], whereas the prevalence of paresthesia varies between 6% and 33% [15,37]. Miller et al [36] detected peripheral nerve injury in the upper extremity in 15 of the 114 COVID-19 patients hospitalized in the prone position and treated in the intensive care unit for an average of 32.5 days.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, studies that investigated either arthralgia or myalgia in COVID-19 patients reported the rate of patients with myalgia between 13.1% and 60.7% and the rate of patients with arthralgia between 5.7% and 43.6% [8][9][10][11][12][13]. Additionally, neuropathic pain and paresthesia were reported in 21% and 33% of COVID-19 patients, respectively [14,15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Musculoskeletal system symptoms in patients with COVID-19 and the impact of these symptoms on quality of life

Erden

Türk

Erden

et al. 2023

BMR

View full text Add to dashboard Cite

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and also affects the musculoskeletal system. OBJECTIVE: This study was conducted to investigate the musculoskeletal symptoms, type of pain and effect on quality of life in patients presenting with pain after COVID-19. METHODS: This prospective, descriptive study included 97 patients aged 18 years or older who were diagnosed with COVID-19 based on a positive polymerase chain reaction test result, with or without musculoskeletal pain prior to COVID-19 infection. Patients who applied to the post-COVID-19 outpatient clinic with the complaint of pain at least 1 month and maximum 1 year after the diagnosis of COVID-19 were included. Patients’ demographic characteristics and musculoskeletal examination findings were evaluated. The patients were examined, and the questionnaire forms were completed. The pain was assessed using the visual analog scale (VAS), the Douleur-Neuropathique-4 (DN-4) questionnaire, while the quality of life was assessed using the Short Form-36 (SF-36) survey. Patients were divided into groups in terms of gender, age, body mass index. Shapiro-Wilk’s test, the independent samples t-test and the Mann-Whitney U test were used for statistical analyses. RESULTS: The mean age of the patients was 46.5 ± 13.5 years, 30 of them were male. Pain increased in patients with pre-COVID-19 arthralgia and myalgia (p< 0.001). Post-COVID-19 VAS was significantly higher than pre-COVID-19 VAS (7 ± 1.2 vs. 3.2 ± 1.9, p< 0.05). Pre-COVID-19 patients with myalgia had significantly worse SF-36 physical function, social function, pain, general health perception (p< 0.05). The mean scores of females in the SF-36 physical function, pain were significantly worse than males (p< 0.05). According to DN-4, 41 (42.3%) patients had neuropathic pain. There was moderate negative correlation between VAS, DN-4 and SF-36 (p< 0.05). CONCLUSIONS: Arthralgia, myalgia, and neuropathic pain, all of which negatively affect the quality of life, are often observed in the patients infected with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Musculoskeletal system symptoms in patients with COVID-19 and the impact of these symptoms on quality of life

Erden

Türk

Erden

et al. 2023

BMR

View full text Add to dashboard Cite

show abstract

“…The emergence of psychiatric symptoms, including psychological distress, anxiety, depression, sleep disorders, and alterations, has been documented in survivors of severe illnesses ( 120 ), including those recuperated from severe infections with other coronaviruses ( 121 , 122 ). These symptoms appear to be linked with post-traumatic stress, potentially stemming from the isolation these patients experienced ( 123 ). During SARS-COV-2 infection, patients supported with MV may also experience paresthesia, neuropathies, and mobility limitations, which could be connected to the loss of gray matter during the acute phase ( 48 ).…”

Section: Pathophysiology Of Long Covidmentioning

confidence: 99%

Pathophysiological, immunological, and inflammatory features of long COVID

Bohmwald,

Diethelm-Varela,

Rodríguez-Guilarte

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The COVID-19 pandemic continues to cause severe global disruption, resulting in significant excess mortality, overwhelming healthcare systems, and imposing substantial social and economic burdens on nations. While most of the attention and therapeutic efforts have concentrated on the acute phase of the disease, a notable proportion of survivors experience persistent symptoms post-infection clearance. This diverse set of symptoms, loosely categorized as long COVID, presents a potential additional public health crisis. It is estimated that 1 in 5 COVID-19 survivors exhibit clinical manifestations consistent with long COVID. Despite this prevalence, the mechanisms and pathophysiology of long COVID remain poorly understood. Alarmingly, evidence suggests that a significant proportion of cases within this clinical condition develop debilitating or disabling symptoms. Hence, urgent priority should be given to further studies on this condition to equip global public health systems for its management. This review provides an overview of available information on this emerging clinical condition, focusing on the affected individuals’ epidemiology, pathophysiological mechanisms, and immunological and inflammatory profiles.

show abstract

Postintensive care syndrome in COVID-19. Unicentric pilot study. Calm does not come after the storm

Cited by 2 publications

References 22 publications

Musculoskeletal system symptoms in patients with COVID-19 and the impact of these symptoms on quality of life

Musculoskeletal system symptoms in patients with COVID-19 and the impact of these symptoms on quality of life

Pathophysiological, immunological, and inflammatory features of long COVID

Contact Info

Product

Resources

About